Literature DB >> 34551374

Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease.

Jennifer L Whitwell1, Nirubol Tosakulwong2, Stephen D Weigand2, Jonathan Graff-Radford3, Nilufer Ertekin-Taner4, Mary M Machulda5, Joseph R Duffy3, Christopher G Schwarz6, Matthew L Senjem7, Clifford R Jack6, Val J Lowe6, Keith A Josephs3.   

Abstract

The apolipoprotein E (APOE) ε4 allele is the most well-established risk factor for Alzheimer's disease (AD), although its relationship to age at onset and clinical phenotype is unclear. We aimed to assess relationships between APOE genotype and age at onset, amyloid-beta (Aβ) deposition and typical versus atypical clinical presentations in AD. Frequency of APOE ε4 carriers by age at onset was assessed in 447 AD patients, 138 atypical AD patients recruited by the Neurodegenerative Research Group at Mayo Clinic, and 309 with typical AD from ADNI. APOE ε4 frequency increased with age at onset in atypical AD but showed a bell-shaped curve in typical AD where highest frequencies were observed between 65 and 70 years. Typical AD showed higher APOE ε4 frequencies than atypical AD only between the ages of 57 and 69 years. Global Aβ standard uptake value ratios did not differ according to APOE e4 status in either group. APOE genotype varies by both age at onset and clinical phenotype in AD, highlighting the heterogeneous nature of AD.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Apolipoprotein; Atypical Alzheimer's disease; Beta-amyloid, PET; Logopenic; Posterior cortical atrophy

Mesh:

Substances:

Year:  2021        PMID: 34551374      PMCID: PMC8616794          DOI: 10.1016/j.neurobiolaging.2021.08.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   5.133


  59 in total

1.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

Review 2.  The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Authors:  William J Jagust; Susan M Landau; Robert A Koeppe; Eric M Reiman; Kewei Chen; Chester A Mathis; Julie C Price; Norman L Foster; Angela Y Wang
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

3.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

4.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Authors:  Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

5.  Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Authors:  R C Petersen; P S Aisen; L A Beckett; M C Donohue; A C Gamst; D J Harvey; C R Jack; W J Jagust; L M Shaw; A W Toga; J Q Trojanowski; M W Weiner
Journal:  Neurology       Date:  2009-12-30       Impact factor: 9.910

6.  TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.

Authors:  Aradhana Sahoo; Alexandre Bejanin; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Matthew L Senjem; Mary M Machulda; Joseph E Parisi; Bradley F Boeve; David S Knopman; Ronald C Petersen; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

Authors:  A Drzezga; T Grimmer; G Henriksen; M Mühlau; R Perneczky; I Miederer; C Praus; C Sorg; A Wohlschläger; M Riemenschneider; H J Wester; H Foerstl; M Schwaiger; A Kurz
Journal:  Neurology       Date:  2009-04-01       Impact factor: 9.910

8.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

9.  Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease.

Authors:  Li Liu; Richard J Caselli
Journal:  Alzheimers Dement (N Y)       Date:  2018-10-30

10.  Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.

Authors:  Niklas Mattsson; Rik Ossenkoppele; Ruben Smith; Olof Strandberg; Tomas Ohlsson; Jonas Jögi; Sebastian Palmqvist; Erik Stomrud; Oskar Hansson
Journal:  Alzheimers Res Ther       Date:  2018-08-07       Impact factor: 6.982

View more
  2 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Six genetically linked mutations in the CD36 gene significantly delay the onset of Alzheimer's disease.

Authors:  Omar Šerý; Tomáš Zeman; Kateřina Sheardová; Martin Vyhnálek; Hana Marková; Jan Laczó; Jan Lochman; Petr Kralik; Kamila Vrzalová; Radka Dziedzinska; Vladimir J Balcar; Jakub Hort
Journal:  Sci Rep       Date:  2022-06-29       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.